Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

doi:10.1016/j.jcte.2022.100306

. 2022 Oct 1;30:100306.

doi: 10.1016/j.jcte.2022.100306. eCollection 2022 Dec.

Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

Léonie Makuété Notemi¹, Lamia Amoura¹, Fatéma Fall Mostaine¹, Laurent Meyer¹, Dominique Paris¹, Samy Talha^{2

3}, Julien Pottecher⁴, Laurence Kessler^{1

5}

Affiliations

¹ Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France.
² Department of Physiology and Functional Explorations, Pole of Thoracic Pathology, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg cedex, France.
³ UR 3072, « Mitochondria, Oxidative Stress and Muscle Protection », CRBS, CS 60026, 1, rue Eugène Boeckel, 67084 Strasbourg Cedex, France.
⁴ Anesthesia-intensive Care Department and Peri-Operative Medicine, Hautepierre Hospital, 1, Avenue Molière, 67098 Strasbourg Cedex, France.
⁵ INSERM UMR 1260 - Regenerative Nanomedicine, Organ Dysfunction and Transplantation, University of Strasbourg, Pharmacy Faculty 74 route du Rhin, 67401 Illkirch, France.

PMID: 36238800
PMCID: PMC9550647
DOI: 10.1016/j.jcte.2022.100306

Free PMC article

Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

Léonie Makuété Notemi et al. J Clin Transl Endocrinol. 2022.

Free PMC article

. 2022 Oct 1;30:100306.

doi: 10.1016/j.jcte.2022.100306. eCollection 2022 Dec.

Authors

Léonie Makuété Notemi¹, Lamia Amoura¹, Fatéma Fall Mostaine¹, Laurent Meyer¹, Dominique Paris¹, Samy Talha^{2

3}, Julien Pottecher⁴, Laurence Kessler^{1

5}

Affiliations

¹ Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France.
² Department of Physiology and Functional Explorations, Pole of Thoracic Pathology, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg cedex, France.
³ UR 3072, « Mitochondria, Oxidative Stress and Muscle Protection », CRBS, CS 60026, 1, rue Eugène Boeckel, 67084 Strasbourg Cedex, France.
⁴ Anesthesia-intensive Care Department and Peri-Operative Medicine, Hautepierre Hospital, 1, Avenue Molière, 67098 Strasbourg Cedex, France.
⁵ INSERM UMR 1260 - Regenerative Nanomedicine, Organ Dysfunction and Transplantation, University of Strasbourg, Pharmacy Faculty 74 route du Rhin, 67401 Illkirch, France.

PMID: 36238800
PMCID: PMC9550647
DOI: 10.1016/j.jcte.2022.100306

Abstract

Objective: Evaluate the efficacy of a new modality of insulin therapy associating both the sensor-augmented pump therapy with predictive low-glucose management (SAP-PLGM) and a telemedicine follow-up in patients with Type 1 diabetes (T1D) in a real-life setting.

Methods: T1D adults under Minimed 640G system with a telemedicine follow-up for glucose management were included in a retrospective study. The primary endpoint was HbA1c while continuous glucose monitoring parameters (CGM) and treatment compliance were the secondary endpoints. These parameters were analyzed according to the therapeutic indication, HbA1c ≥ 8 % (Group A) or severe hypoglycemic events (Group B) and in patients switched to SAP-PLGM therapy.

Results: 62 patients were analyzed with a 28 ± 12 months of follow-up. In Group A, HbA1c decreased from 8.3 ± 0.4 % to 7.7 ± 0.7 % (p < 0.05) and to 7.9 ± 0.3 % (p < 0.05) after 2 and 3 years, respectively. In patients switched to SAP-PLGM therapy, HbA1c decreased from 7.7 ± 0.7 % to 7.2 ± 0.8 % (p < 0.05) at 2 years. After 6 months, the time-below-range (<70 mg/dL) decreased from 2.1 % [0.6-4] to 1.1 % [0.3-2.6] (p < 0.05). Severe hypoglycemic events decreased from 1.62 to 0.5 events/patient/year in Group B (p < 0.05). At 3 years, treatment compliance was 92 % [70-97] in the total population.

Conclusions: Long-term real-life treatment with the SAP-PLGM therapy combined with telemedicine was associated with improved glycemic control in T1D, along with high treatment compliance.

Keywords: CRA, Clinical Research Associate; Continuous glucose monitoring; Hypoglycemia; Insulin pump therapy; Predictive low-glucose management; RN, Registered Nurse.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

**Fig. 1**
Evolution of HbA1c during the 3 years of follow-up in the different groups. A: patients with HbA1c ≥ 8 %; B: patients who had at least one severe hypoglycemia in the year before treatment with the 640G system; patients who switched to the 640G system at the beginning of the study. Data are presented as mean ± SD. *** p < 0.001, ** p < 0.01, * p < 0.05.

See this image and copyright information in PMC

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] IDF_Atlas_10th_Edition_2021.pdf. Accessed March 28, 2022. https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_E....

[2] IDF_Atlas_10th_Edition_2021.pdf. Accessed March 28, 2022. https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_E....

[3] Patterson C.C., Harjutsalo V., Rosenbauer J., Neu A., Cinek O., Skrivarhaug T., et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408–417. - PubMed

[4] Patterson C.C., Harjutsalo V., Rosenbauer J., Neu A., Cinek O., Skrivarhaug T., et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408–417. - PubMed

[5] Tubili C., Pollakova D., Nardone M.R., Di Folco U. Predictive Low Glucose Suspend Algorithm in Real Life: A Five-Year Follow-Up Retrospective Analysis. J Diabetes Sci Technol. 2021;15(6):1303–1307. - PMC - PubMed

[6] Tubili C., Pollakova D., Nardone M.R., Di Folco U. Predictive Low Glucose Suspend Algorithm in Real Life: A Five-Year Follow-Up Retrospective Analysis. J Diabetes Sci Technol. 2021;15(6):1303–1307. - PMC - PubMed

[7] Diabetes Care. 2016;39(5):686–693. doi: 10.2337/dc15-1990. - DOI - PMC - PubMed

[8] Diabetes Care. 2016;39(5):686–693. doi: 10.2337/dc15-1990. - DOI - PMC - PubMed

[9] Saunders A., Messer L.H., Forlenza G.P. MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices. 2019;16(10):845–853. doi: 10.1080/17434440.2019.1670639. - DOI - PMC - PubMed

[10] Saunders A., Messer L.H., Forlenza G.P. MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices. 2019;16(10):845–853. doi: 10.1080/17434440.2019.1670639. - DOI - PMC - PubMed

Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

Affiliations

Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

References

LinkOut - more resources

Full Text Sources

Miscellaneous